New Delhi: The US Food and Drug Administration (FDA) has approved the use of the third dose of Moderna & Johnson & Johnson vaccines against the novel COVID-19 for eligible individuals. In addition, the FDA also approved a “mix and match” booster dose for the currently available approved COVID-19 vaccines.
The FDA said in a press release, “Single booster doses of Janssen COVID-19 vaccine can be used in individuals 18 years of age and older for at least 2 months after completion of the single-dose primary regimen. could.”
“Use of each of the available covid-19 vaccines as a heterogeneous (or “mix and match”) booster dose among eligible individuals after completion of primary immunization with a different available COVID-19 vaccine,” the FDA said.
On Wednesday (October 20, 2021), the agency administered a single booster dose of Moderna COVID-19 vaccine to people 65 years of age and older, 18 to 64 years of age, at least 6 months after the completion of the primary shots. authorized use. Age at high risk of severe Covid-19, and those aged 18 to 64 with persistent institutional or occupational exposure to SARS-CoV-2, Xinhua news agency reported.
For Johnson & Johnson booster doses, the FDA authorized the use of a single booster dose for at least 2 months after completion of the single-dose primary regimen for individuals 18 years of age and older.
A single booster dose of any available COVID-19 vaccine can be administered as a “mix and match” booster dose after completion of primary vaccination with a different available Covid-19 vaccine, according to the FDA.
For example, a person who has received a Johnson & Johnson vaccine may receive one from Moderna or Pfizer-BioNtech as a booster.
“Available data suggest reduced immunity in some populations that have been fully vaccinated,” FDA Acting Commissioner Janet Woodcock said in a statement.
“The availability of these authorized boosters is critical to continued protection against the Covid-19 disease.”
It may be noted that this decision came after an FDA advisory committee voted last week to recommend authorizing Covid-19 booster doses of Moderna and Johnson & Johnson.
Earlier in September, the agency approved the use of the first booster shots for the Pfizer-BioEntech Covid-19 vaccine, allowing a single booster dose of the Pfizer-BioEntech vaccine to be administered to individuals 65 years of age at least after completion of the primary series. To be administered after 6 months. 18 to 64 years of age and older with persistent institutional or occupational exposure to SARS-CoV-2.
a recent study of “mix and match” approach No safety concerns were found from using various vaccines funded by the US National Institutes of Health as boosters.
The study found that people who received the Johnson & Johnson vaccine produced stronger antibody levels after receiving booster shots made by Moderna or Pfizer-BioNtech, compared to boosters from Johnson & Johnson.
(with agency input)